3 results
The primary objective is to determine the efficacy (as measured by pulmonaryfunction) and safety of CNTO 888 in subjects with IPF. The major secondary objectives are to assess theeffect of CNTO 888 on measures of disease progression, to assess the…
Primary objectives: Part A: Generate an airway gene expression signature for itepekimab treatment using RNA sequencing in former smokers with COPDPart B: Validate the airway gene expression signature from Part A in former smokers with COPD in Part…
Primary objectivePrimary population (former smokers cohort):- Evaluate the efficacy of itepekimab compared with placebo on the annualized rate of acute moderate-or-severe COPD exacerbations in former smokers with moderate-to-severe COPD.Secondary…